Through an analysis of posts on Twitter (now rebranded X) relating to obesity published between April 2019 and December 2022, ...

JPMorgan became the second bank in just over a week to downgrade its recommendation on Brazilian stocks, citing a burgeoning budget deficit and the prospect of higher interest rates.

But now JPMorgan has pretty much matched its peers in giving an S&P 500 target of 6,500 for 2025. Analyst forecasts compiled by MarketWatch show a median average for the benchmark index of 6,600 by ...

The loss of bone mineral density and bone mass is called osteoporosis, a disease that affects an estimated 10 million ...

Award-winning authors Crystal Maldonado, Julie Murphy, Renée Watson and Yehudi Mercado chat with Allen Zadoff on why fat and ...

On Tuesday, Vistra Corp (VST) stock saw a modest uptick, ending the day at $162.66 which represents a slight increase of $8.52 or 5.53% from the prior close of $154.14. The stock opened at $154.38 and ...

Without urgent intervention, our study forecasts that more than 80% of adults and close to 60% of adolescents will be ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on ...

Already the go-to drug of choice for millions with type 2 diabetes, metformin might also fight lung cancer if those ...

Barclays lowered the firm’s price target on Workday (WDAY) to $305 from $314 and keeps an Overweight rating on the shares. At face value, the ...